Literature DB >> 33301536

Leprosy in a prison population: A new active search strategy and a prospective clinical analysis.

Fred Bernardes Filho1, Jaci Maria Santana1, Regina Coeli Palma de Almeida1, Glauber Voltan1, Natália Aparecida de Paula1, Marcel Nani Leite1, Claudia Maria Lincoln Silva1, Camila Tormena1, Lean Basoli1, Joelma Menezes2, Moises Batista da Silva3, John Stewart Spencer4, Wilson Marques5, Norma Tiraboschi Foss1, Marco Andrey Cipriani Frade1.   

Abstract

BACKGROUND: This study evaluates an active search strategy for leprosy diagnosis based on responses to a Leprosy Suspicion Questionnaire (LSQ), and analyzing the clinical, immunoepidemiological and follow-up aspects for individuals living in a prison population.
METHODS: A cross-sectional study based on a questionnaire posing 14 questions about leprosy symptoms and signs that was distributed to 1,400 prisoners. This was followed by dermatoneurological examination, anti-PGL-I serology and RLEP-PCR. Those without leprosy were placed in the Non-leprosy Group (NLG, n = 1,216) and those diagnosed with clinical symptoms of leprosy were placed in the Leprosy Group (LG, n = 34).
FINDINGS: In total, 896 LSQ were returned (64%), and 187 (20.9%) of the responses were deemed as positive for signs/symptoms, answering 2.7 questions on average. Clinically, 1,250 (89.3%) of the prisoners were evaluated resulting in the diagnosis of 34 new cases (LG), based on well-accepted clinical signs and symptoms, a new case detection rate of 2.7% within this population, while the NLG were comprised of 1,216 individuals. The confinement time medians were 39 months in the LG while it was 36 months in the NLG (p>0.05). The 31 leprosy cases who responded to the questionnaire (LSQ+) had an average of 1.5 responses. The symptoms "anesthetized skin area" and "pain in nerves" were most commonly mentioned in the LG while "tingling, numbness in the hands/feet", "sensation of pricks and needles", "pain in nerves" and "spots on the skin" responses were found in more than 30% of questionnaires in the NLG. Clinically, 88.2% had dysesthetic macular skin lesions and 97.1% presented some peripheral nerve impairment, 71.9% with some degree of disability. All cases were multibacillary, confirming a late diagnosis. Anti-PGL-I results in the LG were higher than in the NLG (p<0.0001), while the RLEP-PCR was positive in 11.8% of the patients.
INTERPRETATION: Our findings within the penitentiary demonstrated a hidden prevalence of leprosy, although the individuals diagnosed were likely infected while living in their former communities and not as a result of exposure in the prison. The LSQ proved to be an important screening tool to help identify leprosy cases in prisons.

Entities:  

Year:  2020        PMID: 33301536     DOI: 10.1371/journal.pntd.0008917

Source DB:  PubMed          Journal:  PLoS Negl Trop Dis        ISSN: 1935-2727


  3 in total

1.  Serological Immunoassay for Hansen's Disease Diagnosis and Monitoring Treatment: Anti-Mce1A Antibody Response Among Hansen's Disease Patients and Their Household Contacts in Northeastern Brazil.

Authors:  Filipe Rocha Lima; Fred Bernardes Filho; Vanderson Mayron Granemann Antunes; Jaci Maria Santana; Regina Coeli Palma de Almeida; Diana Mota Toro; Vinicius Fozatti Bragagnollo; Gabriel Martins da Costa Manso; Natália Aparecida de Paula; Eliracema Silva Alves; Lee W Riley; Sérgio Arruda; Marco Andrey Cipriani Frade
Journal:  Front Med (Lausanne)       Date:  2022-06-09

2.  Leprosy case series in the emergency room: A warning sign for a challenging diagnosis.

Authors:  Fred Bernardes-Filho; Filipe Rocha Lima; Glauber Voltan; Natália Aparecida de Paula; Marco Andrey Cipriani Frade
Journal:  Braz J Infect Dis       Date:  2021-10-12       Impact factor: 3.257

3.  Evaluation of altered patterns of tactile sensation in the diagnosis and monitoring of leprosy using the Semmes-Weinstein monofilaments.

Authors:  Marco Andrey Cipriani Frade; Fred Bernardes Filho; Claudia Maria Lincoln Silva; Glauber Voltan; Filipe Rocha Lima; Thania Loyola Cordeiro Abi-Rached; Natália Aparecida de Paula
Journal:  PLoS One       Date:  2022-08-10       Impact factor: 3.752

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.